Analysts are on the Bearish side about Theravance Biopharma, Inc. (NASDAQ:TBPH) this week.

July 16, 2018 - By Robert Shackelford

Theravance Biopharma, Inc. (NASDAQ:TBPH) LogoInvestors sentiment increased to 1.35 in 2018 Q1. Its up 0.04, from 1.31 in 2017Q4. It increased, as 6 investors sold Theravance Biopharma, Inc. shares while 25 reduced holdings. 14 funds opened positions while 28 raised stakes. 35.61 million shares or 1.57% more from 35.06 million shares in 2017Q4 were reported.
Whittier stated it has 484 shares. Fmr reported 0.02% of its portfolio in Theravance Biopharma, Inc. (NASDAQ:TBPH). Rock Springs Capital Management Lp owns 0.68% invested in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 652,600 shares. 72,869 were accumulated by D E Shaw And Incorporated. Bank Of America Corporation De holds 0% or 35,978 shares in its portfolio. Swiss National Bank holds 0% or 75,142 shares in its portfolio. Foundation Asset Ltd Partnership has invested 3.59% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Quantbot Lp, a New York-based fund reported 411 shares. Jpmorgan Chase And Com holds 0% of its portfolio in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 9,892 shares. Barclays Plc, United Kingdom-based fund reported 11,825 shares. 121,400 are held by Pictet Asset Mngmt. Price T Rowe Associates Inc Md reported 0.01% of its portfolio in Theravance Biopharma, Inc. (NASDAQ:TBPH). Public Employees Retirement Association Of Colorado has invested 0% of its portfolio in Theravance Biopharma, Inc. (NASDAQ:TBPH). 660 are held by Tower Rech Limited Com (Trc). Geode Mgmt Lc, Massachusetts-based fund reported 393,009 shares.

Since May 18, 2018, it had 1 insider buy, and 2 sales for $556,864 activity. GALA RENEE D sold $242,877 worth of Theravance Biopharma, Inc. (NASDAQ:TBPH) on Friday, May 18. MALKIEL BURTON G had bought 1,000 shares worth $22,540.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Ratings Coverage

Among 3 analysts covering Theravance Biopharma (NASDAQ:TBPH), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Theravance Biopharma had 4 analyst reports since February 8, 2018 according to SRatingsIntel. As per Thursday, March 29, the company rating was initiated by Piper Jaffray. Cantor Fitzgerald maintained Theravance Biopharma, Inc. (NASDAQ:TBPH) on Tuesday, February 27 with “Buy” rating. The stock of Theravance Biopharma, Inc. (NASDAQ:TBPH) has “Buy” rating given on Tuesday, May 8 by Cantor Fitzgerald. The stock has “Outperform” rating by Leerink Swann on Thursday, February 8. Below is a list of Theravance Biopharma, Inc. (NASDAQ:TBPH) latest ratings and price target changes.

08/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $55.0000 Maintain
29/03/2018 Broker: Piper Jaffray Rating: Buy New Target: $45.0000 Initiate
27/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $55.0 Maintain
08/02/2018 Broker: Leerink Swann Rating: Outperform Old Target: $45 New Target: $48 Maintain

The stock decreased 2.48% or $0.65 during the last trading session, reaching $25.61. About 50,858 shares traded. Theravance Biopharma, Inc. (NASDAQ:TBPH) has declined 36.55% since July 16, 2017 and is downtrending. It has underperformed by 49.12% the S&P500.

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company has market cap of $1.41 billion. The firm offers VIBATIV , a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. It currently has negative earnings. The Company’s product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases.

Another recent and important Theravance Biopharma, Inc. (NASDAQ:TBPH) news was published by 247Wallst.com which published an article titled: “Major Biopharma Catalysts on July’s FDA Calendar” on July 07, 2018.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.